Evaluation on the Drug–Polymer Mixing Status in Amorphous Solid Dispersions at the Early Stage Formulation and Process Development

被引:1
作者
Hua (May) Ma
Duk Soon Choi
Yu-E Zhang
Hung Tian
Navnit Shah
Hitesh P. Chokshi
机构
[1] Hoffmann-La Roche Inc.,pRED, Pharmaceutical Research and Early Development, Formulation Research
[2] GlaxoSmithKline (GSK) Consumer Healthcare,undefined
来源
Journal of Pharmaceutical Innovation | 2013年 / 8卷
关键词
Amorphous solid dispersion; Physical stability; Drug–polymer mixing; Homogeneity; NIR chemical imaging (NIR CI); Principal component analysis (PCA); Transmission electron microscopy (TEM); Energy-dispersive X-ray spectroscopy (EDS); Powder X-ray diffraction (PXRD); Differential scanning calorimetry (DSC);
D O I
暂无
中图分类号
学科分类号
摘要
Drug and polymer mixing status in amorphous solid dispersions, an important aspect with regard to the physical stability and in vivo performance of such systems, was evaluated in this report with two case studies. In the first case study, the mixing between the drug and the polymer in an amorphous solid dispersion was assessed at both particulate and bulk levels to ensure that a homogeneous solid dispersion was obtained. In the second study, drug–polymer distribution evaluation in amorphous solid dispersions facilitated the selection of an optimal drug loading and a robust manufacturing process at the early stage of formulation development. Through these two case studies, it is suggested that establishing a multi-faceted characterization approach for amorphous solid dispersions is key to achieve a better understanding of these complex systems and successful delivery of stable and efficacious amorphous formulations.
引用
收藏
页码:163 / 174
页数:11
相关论文
共 160 条
[1]  
Engers D(2010)A solid-state approach to enable early development compounds: selection and animal bioavailability studies of an itraconazole amorphous solid dispersion J Pharm Sci 99 3901-22
[2]  
Teng J(2008)Enhanced bioavailability of a poorly soluble VR1 antagonist using an amorphous solid dispersion approach: a case study Mol Pharm 5 981-93
[3]  
Jimenez-Novoa J(2010)Improved dissolution and pharmacokinetic behavior of cyclosporine A using high-energy amorphous solid dispersion approach Int J Pharm 399 94-101
[4]  
Gent P(1999)Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs J Pharm Sci Us 88 1058-66
[5]  
Hossack S(2004)Amorphous pharmaceutical solids Bosn J Basic Med Sci 4 35-9
[6]  
Campbell C(2001)Amorphous pharmaceutical solids: preparation, characterization and stabilization Adv Drug Deliv Rev 48 27-42
[7]  
Kennedy M(2012)Formulation and process design for a solid dosage form containing a spray-dried amorphous dispersion of ibipinabant Pharm Dev Technol 18 359-66
[8]  
Hu J(2005)Solid dispersion particles of amorphous indomethacin with fine porous silica particles by using spray-drying method Int J Pharm 293 155-64
[9]  
Gao P(2008)Evaluation of solid state properties of solid dispersions prepared by hot-melt extrusion and solvent co-precipitation Int J Pharm 355 141-9
[10]  
Li L(2005)Characterization of physico-mechanical properties of indomethacin and polymers to assess their suitability for hot-melt extrusion processs as a means to manufacture solid dispersion/solution J Pharm Sci Us 94 2463-74